天合光能(688599.SH):“年產3GW高效單晶切半組件項目”等等結項
格隆匯7月2日丨天合光能(688599.SH)公佈,2021年7月1日,公司召開第二屆董事會第七次會議和第二屆監事會第七次會議,經全體董事和監事一致同意,審議通過了《關於首次公開發行股票募投項目結項並將節餘募集資金永久補充流動資金的議案》,同意公司將首次公開發行募集資金投資項目“銅川光伏發電技術領跑基地宜君縣天興250MWp光伏發電項目”、“年產3GW高效單晶切半組件項目”、“研發及信息中心升級建設項目”結項並將節餘募集資金用於永久補充公司流動資金。獨立董事發表了明確的同意意見。該議案無需提交公司股東大會審議。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.